ACAD Acadia Pharmaceuticals Inc.

ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach.

AMTX, ACAD, and REZI are drawing attention from options bears

Acadia Pharmaceuticals has seen its share price fall sharply over the past month, and that pullback is pushing investors to ask whether the current valuation still lines up with what the business is earning today. With the stock under pressure and expectations around its drug pipeline shifting, the key issue is how much of those earnings are already reflected in the price. The share price is down 29.0% over the past month. That puts fresh focus on whether recent weakness has moved Acadia...

Acadia stock falls 13% after its Alzheimer's psychosis study narrowly misses its primary goal, though 60 mg results support continued phase III development.

Acadia hopes to become one of the first companies to secure approval for a therapy specifically indicated for ADP.

Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.

ACADIA Pharmaceuticals (NASDAQ:ACAD) fell for a fifth consecutive day on Thursday, shedding 12.78 percent to close at $22.18 apiece, after earning a sell recommendation from Goldman Sachs. In its market note, the investment firm reiterated its sell recommendation and $17 price target on the stock after missing its primary endpoint in its phase 2 study […]

Key Stats for Acadia Pharmaceuticals StockToday’s Performance: -19%52-Week Range: $20 to $31Valuation Model Target Price: $34Implied Upside: 54%What Happened?Acadia Pharmaceuticals stock (NASDAQ: ACAD) is facing a major test over whether remlifanserin still has a credible path forward in Alzheimer’s disease psychosis after its Phase 2 trial narrowly missed its main goal. Remlifanserin is being developed to treat hallucinations and delusions associated with Alzheimer’s disease psychosis, an indic

Citi’s Yigal Nochomovitz trimmed his price target to $33 from $40 and kept a Buy rating following the company’s update.

Acadia stock tumbled Thursday after the company's experimental Alzheimer's disease psychosis treatment missed the mark in a Phase 2 study.

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index increasing 0.9

Shares of Acadia Pharmaceuticals (NASDAQ:ACAD) fell more than 9% Thursday morning after the company reported mixed Phase 2 results for remlifanserin, its experimental treatment for Alzheimer's disease psychosis. The once-daily 60 mg dose eased hallucinations and delusions more than placebo...

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported top-line results from the phase II portion of its RADIANT clinical program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis, or ADP. The company said the 60 mg once-daily dose narrowly missed statist

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares fell 6% after the company reported results from its Phase 2 RADIANT study of remlifanserin in Alzheimer’s disease psychosis, with the trial missing its primary endpoint while meeting a key secondary measure at nominal statistical significance.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.4%, and the actively t

ACADIA Pharmaceuticals' (ACAD) shares dropped 10% pre-bell after it reported that its phase 2 RADIAN

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.

ACADIA Pharmaceuticals (NASDAQ:ACAD) outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer’s disease psychosis during a discussion hosted by Canaccord Genuity. Thomas Garner, Acadia’s chief comme

Revenue hit $308 million with 17% growth, driven by DAYBUE and NUPLAZID demand.

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Elena Ridloff to its board of directors, the biotechnology company said Monday. Ridloff currently serves as CFO at Sionna Therapeutics. She previously held the same role at ACADIA Pharmaceuticals, where she helped raise $600 million in capital and...

Acadia Pharmaceuticals (ACAD) could benefit from wider Daybue use, steady Nuplazid growth, higher ca

ACADIA Pharmaceuticals has seen its fair value price target adjusted from US$31.80 to US$33.25 per share, reflecting updated assumptions around its business outlook. Recent analyst commentary generally sounds constructive, with higher targets often linked to execution on Daybue and Nuplazid and anticipation around upcoming remlifanserin data, while still pointing out clinical and commercial uncertainties. As you read on, you will see how these shifting targets fit into the broader analyst...

Here is how Acadia Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Acadia Pharmaceuticals (ACAD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals, CVS Health, and Eli Lilly stand out as healthcare names combining resilient business models with strong earnings momentum.

Acadia beats Q2 earnings and revenue estimates as strong Daybue and Nuplazid sales lift results and prompt the company to raise its 2026 revenue outlook.

ACADIA Pharmaceuticals Inc (ACAD) reports 17% revenue growth in Q2 2026, driven by Debut's 30% surge and Nuplazid's steady gains, while advancing its pipeline and European expansion.

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported second-quarter 2026 revenue of $308 million, representing 17% year-over-year growth on an adjusted basis, as sales of its Rett syndrome therapy DAYBUE and Parkinson’s disease psychosis treatment NUPLAZID increased. Chief Executive Officer Catherine Owen

Acadia (ACAD) delivered earnings and revenue surprises of +200.00% and +4.81%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

VTRS readies Q2 results as growth in key markets and brands may offset manufacturing and pricing headwinds across parts of its portfolio.

OTLK heads into Q3 results with investors watching European Lytenava sales, U.S. launch plans and updates after its landmark FDA approval.

HRMY vs. ACAD: Which Stock Is the Better Value Option?

ACADIA Pharmaceuticals stock has delivered a 25.1% gain over the past five years, and the latest valuation checks still suggest the shares screen as attractively priced rather than stretched. With fresh attention on the company after the U.S. FDA granted Fast Track designation to remlifanserin for Alzheimer’s disease psychosis, investors are weighing how much of that potential is already in the price. Over the last 5 years, ACADIA Pharmaceuticals has returned 25.1%, which points to a...

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVS, CAH, HUM and ACAD show favorable earnings indicators ahead of Q2 results as healthcare demand stays resilient despite margin pressures.

HRMY, ACAD, BIIB, INSM and AGIO are set to report Q2 results, with positive Earnings ESPs suggesting potential earnings surprises.

Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.

CVS, CAH, HUM and ACAD look ready for Q2 2026 earnings beats as growing demand for medical products and services continues to support performance.

NBIX heads into Q2 results with a focus on Ingrezza sales, Crenessity growth and pipeline updates as investors watch key commercial and clinical progress.

The mean of analysts' price targets for Acadia (ACAD) points to a 30.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

ACAD wins FDA's Fast Track status for remlifanserin in Alzheimer's disease psychosis as its phase II data readout approaches and phase III enrollment advances.